Canagliflozin reduced the risk of death or hospitalization for heart failure by 22 percent among patients with type 2 diabetes and a high risk of cardiovascular disease, according to results of the CANVAS trial presented March 11 at the American College of Cardiology’s scientific session and published simultaneously in Circulation.
Increased exposure to air pollution may contribute to the higher risk of heart disease found in the black population, researchers reported in Arteriosclerosis, Thrombosis and Vascular Biology.
Avoidance and mixed signals have long plagued the palliative care discussion in cardiology, but that could be changing, according to research presented at the American College of Cardiology’s 67th annual meeting in Orlando, Florida.
Applying natural language learning and deep neural networks to mortality risk models could help predict cardiovascular outcomes with more accuracy than modern support vector machines, researchers said at the 67th annual American College of Cardiology conference in Orlando.
Siemens’ healthcare division, Siemens Healthineers, began trading on Germany’s stock exchange Friday, raising $5.2 billion (4.2 billion euros) by selling 15 percent of the company. Shares of were issued at 28 euros each but opened at 29.10 euros each.
A new trial suggested patients exhibiting patent foramen ovale (PFO), who received a medical device to close the opening in the heart after a stroke, had better outcomes compared to patients who received only stroke-preventing medications.
Avoidance and mixed signals have long plagued the palliative care discussion in cardiology, but that could be changing, according to research presented at the American College of Cardiology’s 67th annual meeting in Orlando, Florida.
Women outpaced men in medical school enrollment for the first time in 2017, but a new report shows they’re entering a profession where the gender pay gap is only growing.
Elizabeth Holmes, a Stanford University dropout once likened to Steve Jobs, was forced to pay a $500,000 fine and give up her blood-testing company Theranos after securities regulators said she fraudulently raised more than $700 million from investors.
